Elevated Level of Soluble HLA Class I Antigens in Serum and Bronchoalveolar Lavage Fluid in Patients with Sarcoidosis.
-
- OGISU Nobuo
- the Second Department of Internal Medicine, Nagoya City University, Medical School
-
- SATO Shigeki
- the Second Department of Internal Medicine, Nagoya City University, Medical School
-
- KAWAGUCHI Haruhiko
- the Second Department of Internal Medicine, Nagoya City University, Medical School
-
- SUGIURA Yoshiki
- the Second Department of Internal Medicine, Nagoya City University, Medical School
-
- MORI Toshiyuki
- the Second Department of Internal Medicine, Nagoya City University, Medical School
-
- NIIMI Takashi
- the Second Department of Internal Medicine, Nagoya City University, Medical School
-
- MAEDA Hiroyoshi
- the Second Department of Internal Medicine, Nagoya City University, Medical School
-
- AKITA Kenji
- the Second Department of Internal Medicine, Nagoya City University, Medical School
-
- YAMADA Yuka
- the Second Department of Internal Medicine, Nagoya City University, Medical School
-
- UEDA Ryuzo
- the Second Department of Internal Medicine, Nagoya City University, Medical School
Bibliographic Information
- Other Title
-
- Elevated Level of Soluble HLA Class 1 Antigens in Serum and Bronchoalveolar Lavage Fluid in Patients with Sarcoidosis
Search this article
Description
Objective Soluble HLA class I antigens (sHLAs) in human serum have been reported to be associated with allografts and autoimmune disease and could modify immunological reactions induced by membrane type HLAs. To investigate the clinical significance of sHLAs in sarcoidosis, we assessed concentrations of sHLAs in both serum and bronchoalveolar lavage fluid (BALF) and also examined their production by peripheral blood mononuclear cells (PBMCs) and BALF cells.<br> Methods Concentrations of sHLAs were determined by enzyme-linked immunosorbent assay, using a monoclonal antibody against HLA class I (W6/32) and an enzyme-labeled polyclonal antibody to human β2-microglobulin. PBMCs and BALF cells were cultured in the presence or absence of either LPS or PHA.<br> Patients Serum levels of sHLAs were assessed in 96 patients with sarcoidosis and in 32 healthy control subjects. sHLAs concentrations in BALF were also investigated in 17 active sarcoidosis patients and in 13 control subjects.<br> Results sHLAs levels in both serum and BALF were higher in sarcoidosis cases than in control subjects (p<0.05, in both). In the patients, values were significantly higher in active than in inactive stages (p<0.001) and significantly correlated with angiotensin-converting enzyme (ACE) levels. Both PBMCs and BALF cells produced enhanced amounts of sHLAs in patients with active sarcoidosis compared with those in control subjects.<br> Conclusion These results demonstrated that the level of sHLAs in serum is a useful index of disease activity of sarcoidosis, partly reflecting production by PBMCs and BALF cells.<br>(Internal Medicine 40: 201-207, 2001)
Journal
-
- Internal Medicine
-
Internal Medicine 40 (3), 201-207, 2001
The Japanese Society of Internal Medicine
- Tweet
Keywords
Details 詳細情報について
-
- CRID
- 1390001204868436480
-
- NII Article ID
- 10006999024
-
- NII Book ID
- AA10827774
-
- COI
- 1:CAS:528:DC%2BD3MXkt1Ois7w%3D
-
- ISSN
- 13497235
- 09182918
-
- NDL BIB ID
- 5702897
-
- PubMed
- 11310485
-
- Text Lang
- en
-
- Data Source
-
- JaLC
- NDL
- Crossref
- PubMed
- CiNii Articles
-
- Abstract License Flag
- Disallowed